Genes and environment: effects on the development of second malignancies in retinoblastoma survivors

References

• Eng C, Li FP, Abramson DH et al. Mortality from second tumors among long-term survivors of retinoblastoma. J. Natl Cancer Inst.85(14), 1121–1128 (1993).
   PubMed Web of Science ®Google Scholar
• Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology105(4), 573–579 (1998).
   PubMed Web of Science ®Google Scholar
• Moll AC, Imhof SM, Schouten-Van Meeteren AY et al. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? Ophthalmology108(6), 1109–1114 (2001).
   PubMed Web of Science ®Google Scholar
• Li FP, Abramson DH, Tarone RE et al. Hereditary retinoblastoma, lipoma, and second primary cancers. J. Natl Cancer Inst.89(1), 83–84 (1997).
   PubMedGoogle Scholar
• Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology108(10), 1868–1876 (2001).
   PubMedGoogle Scholar
• Wong FL, Boice JD Jr, Abramson DH et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA278(15), 1262–1267 (1997).
   PubMed Web of Science ®Google Scholar
• Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer53(5), 661–671 (1986).
   PubMed Web of Science ®Google Scholar
• Derkinderen DJ, Koten JW, Wolterbeek R et al. Non-ocular cancer in hereditary retinoblastoma survivors and relatives. Ophthalmic. Paediatr. Genet.8(1), 23–25 (1987).
   PubMed Web of Science ®Google Scholar
• Moll AC, Imhof SM, Bouter LM, Tan KE. Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic. Genet.18(1), 27–34 (1997).
   PubMed Web of Science ®Google Scholar
• Fletcher O, Easton D, Anderson K et al. Lifetime risks of common cancers among retinoblastoma survivors. J. Natl Cancer Inst.96(5), 357–363 (2004).
   PubMedGoogle Scholar
• Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr. Radiol.36(Suppl. 14), 121–125 (2006).
   PubMedGoogle Scholar
• Abramson DH, Du TT, Beaverson KL. (Neonatal) retinoblastoma in the first month of life. Arch. Ophthalmol.120(6), 738–742 (2002).
   PubMedGoogle Scholar
• Moll AC, Kuik DJ, Bouter LM et al. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862–1995. Br. J. Ophthalmol.81(7), 559–562 (1997).
   PubMed Web of Science ®Google Scholar
• Kleinerman RA, Tucker MA, Tarone RE et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol.23(10), 2272–2279 (2005).
   PubMed Web of Science ®Google Scholar
• Sippel KC, Fraioli RE, Smith GD et al. Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am. J. Hum. Genet.62(3), 610–619 (1998).
   PubMed Web of Science ®Google Scholar
• Duesberg P. Chromosomal chaos and cancer. Sci. Am.296(5), 52–59 (2007).
   PubMedGoogle Scholar
• Mastrangelo D, De Francesco S, Di Leonardo A et al. Retinoblastoma epidemiology: does the evidence matter? Eur. J. Cancer43(10), 1596–1603 (2007).
   Google Scholar
• Health risks from exposure to low levels of ionizing radiation. In: Biological effects of ionizing radiation. National Academies Press, DC, USA 406 (2006).
   Google Scholar
• Tubiana M, Aurengo A, Averbeck D, Masse R. Recent reports on the effect of low doses of ionizing radiation and its dose-effect relationship. Radiat. Environ. Biophys.44(4), 245–251 (2006).
   PubMed Web of Science ®Google Scholar
• Aerts I, Pacquement H, Doz F et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur. J. Cancer40(10), 1522–1529 (2004).
   PubMedGoogle Scholar
• Sagerman RH, Cassady JR, Tretter P, Ellsworth RM. Radiation induced neoplasia following external beam therapy for children with retinoblastoma. Am. J. Roentgenol. Radium. Ther. Nucl. Med.105(3), 529–535 (1969).
   PubMedGoogle Scholar
• Abramson DH. Retinoblastoma in the 20th Century: past success and future challenges the Weisenfeld lecture. Invest. Ophthalmol. Vis. Sci.46(8), 2683–2691 (2005).
   PubMed Web of Science ®Google Scholar
• Chauveinc L, Mosseri V, Quintana E et al. Osteosarcoma following retinoblastoma: age at onset and latency period. Ophthalmic. Genet.22(2), 77–88 (2001).
   PubMedGoogle Scholar
• Kleinerman RA, Abramson DH. Second cancers in retinoblastoma: what is the risk with modern radiotherapy and no chemotherapy? In: International Society of Ocular Oncology. Siena, Italy (2007).
   Google Scholar
• Klein G, Michaelis J, Spix C et al. Second malignant neoplasms after treatment of childhood cancer. Eur. J. Cancer39(6), 808–817 (2003).
   PubMedGoogle Scholar
• Travis LB, Curtis RE, Stovall M et al. Risk of leukemia following treatment for non-Hodgkin’s lymphoma. J. Natl Cancer Inst.86(19), 1450–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Hawkins MM, Wilson LM, Stovall MA et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukemia after childhood cancer. BMJ304(6832), 951–958 (1992).
   PubMed Web of Science ®Google Scholar
• Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med.325(24), 1682–1687 (1991).
   PubMed Web of Science ®Google Scholar
• Loning L, Zimmermann M, Reiter A et al. Secondary neoplasms subsequent to Berlin–Frankfurt–Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood95(9), 2770–2775 (2000).
   PubMed Web of Science ®Google Scholar
• Leung W, Sandlund JT, Hudson MM et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer92(7), 1959–1966 (2001).
   PubMed Web of Science ®Google Scholar
• Shearer P, Kapoor G, Beckwith JB et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J. Pediatr. Hematol. Oncol.23(2), 109–111 (2001).
   PubMed Web of Science ®Google Scholar
• Rivera GK, Pui CH, Santana VM et al. Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother. Pharmacol.34(Suppl.), S89–S95 (1994).
   Web of Science ®Google Scholar
• Stine KC, Saylors RI, Sawyer JR, Becton DL. Secondary acute myeloid leukemia following safe exposure to etoposide. J. Clin. Oncol.15, 1583–1586 (1997).
   PubMed Web of Science ®Google Scholar
• Gombos DS, Hungerford J, Abramson DH et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology114(7), 1378–1383 (2007).
   PubMed Web of Science ®Google Scholar
• Weintraub M, Revel-Vilk S, Charit M et al. Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma. J. Pediatr. Hematol. Oncol.29(9), 646–648 (2007).
   PubMedGoogle Scholar
• Ergun-Longmire B, Mertens AC, Mitby P et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol. Metab.91(9), 3494–3498 (2006).
   PubMed Web of Science ®Google Scholar
• Abramson DH, Lee TC, Driscoll C. Osteogenic sarcoma in a survivor of metastatic germline retinoblastoma: the possible influence of human growth hormone. J. Pediatr. Ophthalmol. Strabismus39, 347–348 (2002).
   PubMedGoogle Scholar
• Slootweg MC, Ohlsson C, van Elk EJ et al. Growth hormone receptor activity is stimulated by insulin-like growth factor binding protein 5 in rat osteosarcoma cells. Growth Regul.6(4), 238–246 (1996).
   PubMedGoogle Scholar
• Varley JM. Germline TP53 mutations and Li–Fraumeni syndrome. Hum. Mutat.21(3), 313–320 (2003).
   PubMed Web of Science ®Google Scholar
• Kleinerman RA, Tucker MA, Abramson DH et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J. Natl Cancer Inst.99(1), 24–31 (2007).
   PubMed Web of Science ®Google Scholar
• Smith JL, Bedford MA. Retinoblastomas. In: Tumours in children. Marsden HB, Steward JK (Eds). Berli, Springer–Verlag, Germany 245–281 (1976).
   Google Scholar
• Sanders BM, Jay M, Draper GJ, Roberts EM. Non-ocular cancer in relatives of retinoblastoma patients. Br. J. Cancer60(3), 358–365 (1989).
   PubMed Web of Science ®Google Scholar
• Kleinerman RA, Tarone RE, Abramson DH et al. Hereditary retinoblastoma and risk of lung cancer. J. Natl Cancer Inst.92(24), 2037–2039 (2000).
   PubMedGoogle Scholar
• Foster MC, Kleinerman RA, Abramson DH et al. Tobacco use in adult long-term survivors of retinoblastoma. Cancer Epidemiol. Biomarkers Prev.15(8), 1464–1468 (2006).
   PubMedGoogle Scholar
• Blach LE, McCormick B, Abramson DH, Ellsworth RM. Trilateral retinoblastoma – incidence and outcome: a decade of experience. Int. J. Radiat. Oncol. Biol. Phys.29(4), 729–733 (1994).
   PubMed Web of Science ®Google Scholar
• Paulino AC. Trilateral retinoblastoma: is the location of the intracranial tumor important? Cancer86(1), 135–141 (1999).
   PubMedGoogle Scholar
• Souweidane MM, Dunkel IJ, Abramson DH. Pineal region tumors: contemporary surgical management and implications for children with trilateral retinoblastoma. In: International Society of Ocular Oncology. Siena, Italy (2007).
   Google Scholar
• Shields CL, Meadows AT, Shields JA et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch. Ophthalmol.119(9), 1269–1272 (2001).
   PubMedGoogle Scholar
• Moll AC, Imhof SM, Schouten-Van Meeteren AY, Boers M. Screening for pineoblastoma in patients with retinoblastoma. Arch. Ophthalmol.120(12), 1774 author reply (2002).
   PubMedGoogle Scholar
• Genuardi M, Klutz M, Devriendt K et al. Multiple lipomas linked to an RB1 gene mutation in a large pedigree with low penetrance retinoblastoma. Eur. J. Hum. Genet.9(9), 690–694 (2001).
   PubMedGoogle Scholar
• Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. Am. J. Roentgenol.176(2), 289–296 (2001).
   PubMed Web of Science ®Google Scholar
• Mills DM, Tsai S, Meyer DR, Belden C. Pediatric ophthalmic computed tomographic scanning and associated cancer risk. Am. J. Ophthalmol.142(6), 1046–1053 (2006).
   PubMedGoogle Scholar
• Vazquez E, Castellote A, Piqueras J et al. Second malignancies in pediatric patients: imaging findings and differential diagnosis. Radiographics23(5), 1155–1172 (2003).
   PubMedGoogle Scholar
• Duncan JL, Scott IU, Murray TG et al. Routine neuroimaging in retinoblastoma for the detection of intracranial tumors. Arch. Ophthalmol.119(3), 450–452 (2001).
   PubMedGoogle Scholar
• Cumber H. Risk of sarcoma increased in survivors of retinoblastoma. Lancet Oncol.8(2), 104 (2007).
   PubMedGoogle Scholar
• Friedman DL, Freyer DR, Levitt GA. Models of care for survivors of childhood cancer. Pediatr. Blood Cancer46(2), 159–168 (2006).
   PubMed Web of Science ®Google Scholar
• Lohmann DR. RB1 gene mutations in retinoblastoma. Hum. Mutat.14(4), 283–288 (1999).
   PubMed Web of Science ®Google Scholar
• Nichols KE, Houseknecht MD, Godmilow L et al. Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. Hum. Mutat.25(6), 566–574 (2005).
   PubMedGoogle Scholar
• Mastrangelo D, Squitieri N, Bruni S et al. The polymerase chain reaction (PCR) in the routine genetic characterization of retinoblastoma: a tool for the clinical laboratory. Surv. Ophthalmol.41(4), 331–340 (1997).
   PubMedGoogle Scholar
• Lohmann DR, Brandt B, Hopping W et al. The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. Am. J. Hum. Genet.58(5), 940–949 (1996).
   PubMed Web of Science ®Google Scholar
• Bartova E, Kozubek S, Gajova H et al. Cytogenetics and cytology of retinoblastomas. J. Cancer Res. Clin. Oncol.129(2), 89–99 (2003).
   PubMedGoogle Scholar
• Rotchell JM, Scoggins B, Blair JB, Ostrander GK. Isolation and characterization of the retinoblastoma protein from fish. Comp. Biochem. Physiol. B. Biochem. Mol. Biol.130(3), 385–391 (2001).
   PubMedGoogle Scholar
• Tsai T, Fulton L, Smith BJ et al. Rapid identification of germline mutations in retinoblastoma by protein truncation testing. Arch. Ophthalmol.122(2), 239–248 (2004).
   PubMedGoogle Scholar
• Houdayer C, Gauthier-Villars M, Lauge A et al. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum. Mutat.23(2), 193–202 (2004).
   PubMed Web of Science ®Google Scholar
• Sellner LN, Edkins E, Smith N. Screening for RB1 mutations in tumor tissue using denaturing high performance liquid chromatography, multiplex ligation-dependent probe amplification, and loss of heterozygosity analysis. Pediatr. Dev. Pathol.9(1), 31–37 (2006).
   PubMedGoogle Scholar
• Gallie BL. Predictive testing for retinoblastoma comes of age. Am. J. Hum. Genet.61(2), 279–281 (1997).
   PubMedGoogle Scholar
• Schefler AC, Abramson DH, Huryn LA. Second primary neoplasms in retinoblastoma: effect of gene and environment. In: Principles and Practice of Ophthalmology. (3rd Edition). Albert DM, Miller J (Eds). WB, USA. Saunders & Co. PA, USA (2007).
   Google Scholar
• Abramson DH, Schefler AC. Update on Retinoblastoma. Retina24(6), 828–848 (2004).
   PubMed Web of Science ®Google Scholar